Immunovant director awarded RSUs and options
Immunovant, Inc. director Frank Torti reported equity awards consisting of stock options and restricted stock units as part of his compensation.
Rhea-AI Filing Summary
Immunovant, Inc. director Frank Torti reported equity awards consisting of stock options and restricted stock units as part of his compensation. He received options for 88,325 shares of common stock at an exercise price of $24.61 per share, expiring in 2036. He was also granted 174,189 restricted stock units (RSUs), each representing one share of common stock upon vesting. Both the options and RSUs vest in substantially equal quarterly installments over two years starting from April 1, 2026, contingent on his continuous service. Following the common stock award, he directly holds 1,009,228 shares of Immunovant common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 262,514 shares
Grant/Award
2 txns
Insider
Torti Frank
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 88,325 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 174,189 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 88,325 contracts (Direct);
Common Stock — 1,009,228 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. These units will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest in substantially equal quarterly installments over two years measured from April 1, 2026, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
RSU grant: 174,189 units
Option grant size: 88,325 shares
Option exercise price: $24.61 per share
+3 more
6 metrics
RSU grant
174,189 units
Each unit represents one share of common stock
Option grant size
88,325 shares
Stock options granted April 7, 2026
Option exercise price
$24.61 per share
Stock option exercise price
Option expiration
April 7, 2036
Stock option expiration date
Post-award holdings
1,009,228 shares
Common stock held directly after grant
Vesting period
2 years
Quarterly vesting from April 1, 2026
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, Rule 409A, continuous service, +1 more
5 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan")."
Rule 409A financial
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A."
continuous service financial
"subject to the Reporting Person's continuous service to the Issuer as of such date."
stock option (right to buy) financial
"security_title: "Stock Option (right to buy)""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunovant (IMVT) grant to director Frank Torti?
Immunovant granted director Frank Torti stock options for 88,325 shares at a $24.61 exercise price and 174,189 restricted stock units. Both awards are part of his equity compensation and relate to Immunovant common stock.
How do Frank Torti’s new Immunovant (IMVT) RSUs vest?
Frank Torti’s 174,189 RSUs vest in substantially equal quarterly installments over two years starting April 1, 2026. Vesting is conditioned on his continuous service with Immunovant, and each unit converts into one share of common stock at settlement.
What are the terms of Frank Torti’s Immunovant (IMVT) stock options?
Torti’s options cover 88,325 Immunovant shares at a $24.61 exercise price and expire in 2036. The underlying shares vest in equal quarterly installments over two years from April 1, 2026, subject to his continued service to the company.
Can Frank Torti defer settlement of his Immunovant (IMVT) RSUs?
Yes. The filing states Torti may elect to defer settlement of his RSUs upon vesting, subject to Rule 409A requirements. This means he can choose to receive the underlying shares at a later date under compliant deferral arrangements.
When do Frank Torti’s Immunovant (IMVT) equity awards start vesting?
Both the RSUs and option awards begin vesting based on a schedule measured from April 1, 2026. They vest in substantially equal quarterly installments over two years, assuming Torti continues to provide service to Immunovant.
AI-generated analysis. How Rhea-AI works. Not financial advice.
